BioSpace News Archive

Cameron Reynolds, Chief Executive Officer of Volition, upon releasing these results commented, “I could not be more proud of our dedicated team at Volition. During 2017, we, together with our collaborators, have made strong progress.”

GAAP total revenues of $64.3 million in 2017 compared to $64.7 million in 2016

“The fourth quarter marked the strongest sales in Tandem’s history, with 80 percent growth in our sequential quarterly pump shipments,” said Kim Blickenstaff, President and Chief Executive Officer.

Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors.

The Company reported net revenue from initial sales of NERLYNX of approximately $20.1 million in the fourth quarter and $26.2 million for the full year 2017.

Ionis Pharmaceuticals, Inc. announced the presentation of positive top-line data from a completed Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington’s disease (HD) at the 13th Annual CHDI HD conference.

Medical benefit drug spending jumps 21 percent in one year.

Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par’s Vasostrict®, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration.

The IOF board of directors has begun identifying the next generation of leaders for the organization.

BostonSight to implement PeerMed, a peer-to-peer telemedicine platform developed by CoolDoctors.